UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification Number) | ||||||
(Address of principal executive offices)
(312 ) 940-2443
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ¨
Securities registered pursuant to Section 12(b) of the Act:
| Title of each Class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Item 2.02. Results of Operations and Financial Condition.
On October 25, 2023 , Option Care Health, Inc. issued a press release reporting its third quarter 2023 financial results. A copy of the press release is furnished with this Form 8-K and attached hereto as Exhibit 99.1.
The press release includes certain non-GAAP financial measures described therein. Reconciliation between any non-GAAP financial measures presented and the most directly comparable GAAP financial measures is also provided.
The information in this Form 8-K and the Exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
| Exhibit No. | Description | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Option Care Health, Inc. | |||||||||||
| Date: | By: | /s/ Michael Shapiro | |||||||||
| Michael Shapiro | |||||||||||
| Chief Financial Officer | |||||||||||
Exhibit 99.1
OPTION CARE HEALTH ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2023
BANNOCKBURN, IL., October 25, 2023 - Option Care Health, Inc. (the “Company” or “Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion services, announced today financial results for the third quarter ended September 30, 2023.
Third Quarter 2023 Financial Results and Highlights
•Net revenue of $1,093.0 million, up 7.1% compared to $1,020.9 million in the third quarter of 2022
•Gross profit of $254.3 million, or 23.3% of net revenue, up 16.6% compared to $218.0 million, or 21.4% of net revenue, in the third quarter of 2022
•Net income of $56.3 million, or $0.31 basic earnings per share, up 45.0% compared to net income of $38.8 million, or $0.21 basic earnings per share, in the third quarter of 2022
•Adjusted EBITDA of $109.8 million, up 28.2% compared to $85.6 million in the third quarter of 2022
•Cash flow from operations of $61.0 million compared to $87.0 million in the third quarter of 2022
•Cash and cash equivalents balance was $386.5 million at the end of the third quarter of 2023
John C. Rademacher, Chief Executive Officer, commented, “The Option Care Health team continues to execute on outstanding clinical outcomes and extraordinary patient care, which helped translate into solid financial results in the third quarter. I am excited to build on this momentum as we close out the year and look forward to seeing the impact we believe the team will make in the post-acute and ambulatory setting in the years to come.”
Updated Full Year 2023 Financial Guidance
For the full year 2023, Option Care Health expects to generate:
•Net revenue of $4.23 billion to $4.28 billion
•Adjusted EBITDA of $420 million to $425 million
•Cash flow from operations of at least $350 million, inclusive of the Amedisys merger termination fee net of merger-related expenses
Additionally, the Company anticipates an effective tax rate of approximately 27% and net interest expense of approximately $52.0 million to $54.0 million.
Conference Call
Option Care Health will host a conference call to discuss its third quarter 2023 financial results later today at 8:30 a.m. EDT. The conference call can be accessed via a live audio webcast that will be available online at https://investors.optioncarehealth.com. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.
About Option Care Health
Option Care Health is the nation’s largest independent provider of home and alternate site infusion services. With over 7,500 team members including more than 4,500 clinicians, we work compassionately to elevate standards of care for patients with acute and chronic conditions in all 50 states. Through our clinical leadership, expertise and national scale, Option Care Health is reimagining the infusion care experience for patients, customers and team members. To learn more, please visit our website at OptionCareHealth.com.
Investor Contacts
| Mike Shapiro | Bob East, Asher Dewhurst, Jordan Kohnstam | ||||
| Chief Financial Officer | Westwicke | ||||
| T: (312) 940-2538 | T: (413) 213-0500 | ||||
| mike.shapiro@optioncare.com | optioncarehealth@westwicke.com | ||||
Forward-Looking Statements - Safe Harbor
This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “believe,” “project,” “estimate,” “expect,” “may,” “should,” “will” and similar references to future periods. Examples of forward-looking statements include, among others, statements we may make regarding future revenues, future earnings, regulatory developments, market developments, new products and growth strategies, integration activities and the effects of any of the foregoing on our future results of operations or financial conditions.
Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: changes in laws and regulations applicable to our business model; changes in market conditions and receptivity to our services and offerings; pending and future litigation; potential liability for claims not covered by insurance; and loss of relationships with managed care organizations and other non-governmental third party payers. For a detailed discussion of the risk factors that could affect our actual results, please refer to the risk factors identified in our periodic reports as filed with the SEC.
Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly
update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Note Regarding Use of Non-GAAP Financial Measures
In addition to reporting financial information in accordance with generally accepted accounting principles (GAAP), the Company is also reporting Adjusted EBITDA, which is a non-GAAP financial measure. Adjusted EBITDA is not a measurement of financial performance under GAAP and should not be used in isolation or as a substitute or alternative to net income, operating income or any other performance measure derived in accordance with GAAP, or as a substitute or alternative to cash flow from operating activities or
a measure of the Company’s liquidity. In addition, the Company's definition of Adjusted EBITDA may not be comparable to similarly titled non-GAAP financial measures reported by other companies. Adjusted EBITDA, as defined by the Company, represents net income before net interest expense, income tax expense, depreciation and amortization, stock-based compensation expense, loss on extinguishment of debt, and restructuring, acquisition, integration and other. As part of restructuring, acquisition, integration and other, the Company may incur significant charges such as the write down of certain long‑lived assets, temporary redundant expenses, professional fees, potential retention and severance costs and potential accelerated payments or termination costs for certain of its contractual obligations. Management believes that Adjusted EBITDA provides useful supplemental information regarding the performance of Option Care Health’s business operations and facilitates comparisons to the Company’s historical operating results. We have not reconciled Adjusted EBITDA guidance to net income as management believes creation of this reconciliation would not be practicable due to the uncertainty regarding, and potential variability of, material reconciling items. For a full reconciliation of Adjusted EBITDA to the most comparable GAAP financial measure, please see below.
Schedule 1
OPTION CARE HEALTH, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(IN THOUSANDS)(UNAUDITED)
| September 30, 2023 | December 31, 2022 | ||||||||||
| ASSETS | |||||||||||
| CURRENT ASSETS: | |||||||||||
| Cash and cash equivalents | $ | 386,489 | $ | 294,186 | |||||||
| Accounts receivable, net | 382,957 | 377,542 | |||||||||
| Inventories | 251,366 | 224,281 | |||||||||
| Prepaid expenses and other current assets | 95,473 | 98,330 | |||||||||
| Total current assets | 1,116,285 | 994,339 | |||||||||
NONCURRENT ASSETS: | |||||||||||
| Property and equipment, net | 107,960 | 108,321 | |||||||||
| Intangible assets, net | 20,868 | 22,371 | |||||||||
| Referral sources, net | 323,126 | 341,744 | |||||||||
| Goodwill | 1,540,246 | 1,533,424 | |||||||||
| Other noncurrent assets | 135,131 | 112,737 | |||||||||
| Total noncurrent assets | 2,127,331 | 2,118,597 | |||||||||
| TOTAL ASSETS | $ | 3,243,616 | $ | 3,112,936 | |||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||||||
| CURRENT LIABILITIES: | |||||||||||
| Accounts payable | $ | 429,536 | $ | 378,763 | |||||||
| Other current liabilities | 194,548 | 186,588 | |||||||||
| Total current liabilities | 624,084 | 565,351 | |||||||||
| NONCURRENT LIABILITIES: | |||||||||||
| Long-term debt, net of discount, deferred financing costs and current portion | 1,057,016 | 1,058,204 | |||||||||
| Other noncurrent liabilities | 122,433 | 103,278 | |||||||||
| Total noncurrent liabilities | 1,179,449 | 1,161,482 | |||||||||
| Total liabilities | 1,803,533 | 1,726,833 | |||||||||
| STOCKHOLDERS’ EQUITY | 1,440,083 | 1,386,103 | |||||||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ | 3,243,616 | $ | 3,112,936 | |||||||
Schedule 2
OPTION CARE HEALTH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS
(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)(UNAUDITED)
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||
| NET REVENUE | $ | 1,093,014 | $ | 1,020,918 | $ | 3,177,934 | $ | 2,917,522 | |||||||||||||||
| COST OF REVENUE | 838,748 | 802,917 | 2,443,834 | 2,281,685 | |||||||||||||||||||
| GROSS PROFIT | 254,266 | 218,001 | 734,100 | 635,837 | |||||||||||||||||||
| OPERATING COSTS AND EXPENSES: | |||||||||||||||||||||||
| Selling, general and administrative expenses | 158,214 | 142,015 | 459,644 | 417,771 | |||||||||||||||||||
| Depreciation and amortization expense | 15,005 | 15,268 | 44,417 | 46,027 | |||||||||||||||||||
| Total operating expenses | 173,219 | 157,283 | 504,061 | 463,798 | |||||||||||||||||||
| OPERATING INCOME | 81,047 | 60,718 | 230,039 | 172,039 | |||||||||||||||||||
| OTHER INCOME (EXPENSE): | |||||||||||||||||||||||
| Interest expense, net | (11,786) | (13,997) | (38,816) | (39,008) | |||||||||||||||||||
| Other, net | 824 | 5,360 | 88,594 | 7,956 | |||||||||||||||||||
| Total other (expense) income | (10,962) | (8,637) | 49,778 | (31,052) | |||||||||||||||||||
| INCOME BEFORE INCOME TAXES | 70,085 | 52,081 | 279,817 | 140,987 | |||||||||||||||||||
| INCOME TAX EXPENSE | 13,783 | 13,258 | 69,904 | 37,960 | |||||||||||||||||||
| NET INCOME | $ | 56,302 | $ | 38,823 | $ | 209,913 | $ | 103,027 | |||||||||||||||
| Earnings per share, basic | $ | 0.31 | $ | 0.21 | $ | 1.17 | $ | 0.57 | |||||||||||||||
| Earnings per share, diluted | $ | 0.31 | $ | 0.21 | $ | 1.16 | $ | 0.57 | |||||||||||||||
| Weighted average common shares outstanding, basic | 178,826 | 181,884 | 179,956 | 180,829 | |||||||||||||||||||
| Weighted average common shares outstanding, diluted | 180,528 | 183,022 | 181,286 | 181,760 | |||||||||||||||||||
Schedule 3
OPTION CARE HEALTH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(IN THOUSANDS)(UNAUDITED)
| Nine Months Ended September 30, | |||||||||||
| 2023 | 2022 | ||||||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | |||||||||||
| Net income | $ | 209,913 | $ | 103,027 | |||||||
| Adjustments to reconcile net income to net cash provided by operations: | |||||||||||
| Depreciation and amortization expense | 46,423 | 49,723 | |||||||||
| Other non-cash adjustments | 54,259 | 66,999 | |||||||||
| Changes in operating assets and liabilities: | |||||||||||
| Accounts receivable, net | (5,075) | (23,153) | |||||||||
| Inventories | (28,362) | (52,749) | |||||||||
| Accounts payable | 50,726 | 129,859 | |||||||||
| Other | (7,558) | (49,614) | |||||||||
| Net cash provided by operating activities | 320,326 | 224,092 | |||||||||
| CASH FLOWS FROM INVESTING ACTIVITIES: | |||||||||||
| Acquisition of property and equipment | (21,981) | (17,111) | |||||||||
| Business acquisitions, net of cash acquired | (12,855) | (87,315) | |||||||||
| Other investing activities | (5,889) | — | |||||||||
| Net cash used in investing activities | (40,725) | (104,426) | |||||||||
| CASH FLOWS FROM FINANCING ACTIVITIES: | |||||||||||
| Purchase of company stock | (175,108) | — | |||||||||
| Proceeds from warrant exercises | — | 20,916 | |||||||||
| Other financing cash flows | (12,190) | (4,537) | |||||||||
| Net cash (used in) provided by financing activities | (187,298) | 16,379 | |||||||||
| NET INCREASE IN CASH AND CASH EQUIVALENTS | 92,303 | 136,045 | |||||||||
| Cash and cash equivalents - beginning of the period | 294,186 | 119,423 | |||||||||
| CASH AND CASH EQUIVALENTS - END OF PERIOD | $ | 386,489 | $ | 255,468 | |||||||
Schedule 4
OPTION CARE HEALTH, INC.
QUARTERLY RECONCILIATION BETWEEN GAAP AND NON-GAAP MEASURES
(IN THOUSANDS)(UNAUDITED)
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||
| Net income | $ | 56,302 | $ | 38,823 | $ | 209,913 | $ | 103,027 | |||||||||||||||
| Interest expense, net | 11,786 | 13,997 | 38,816 | 39,008 | |||||||||||||||||||
| Income tax expense | 13,783 | 13,258 | 69,904 | 37,960 | |||||||||||||||||||
| Depreciation and amortization expense | 15,622 | 16,474 | 46,423 | 49,723 | |||||||||||||||||||
| EBITDA | 97,493 | 82,552 | 365,056 | 229,718 | |||||||||||||||||||
| EBITDA adjustments | |||||||||||||||||||||||
| Stock-based incentive compensation | 9,235 | 4,005 | 22,908 | 12,581 | |||||||||||||||||||
| Restructuring, acquisition, integration and other (1) | 3,029 | (934) | (74,383) | 6,282 | |||||||||||||||||||
| Adjusted EBITDA | $ | 109,757 | $ | 85,623 | $ | 313,581 | $ | 248,581 | |||||||||||||||
(1) Restructuring, acquisition, integration and other for the nine months ended September 30, 2023 includes the Amedisys merger termination fee, net of merger-related expenses